Two Sigma Securities’s Gain Therapeutics GANX Stock Holding History

Two Sigma Securities’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,323	Closed	-$48.4K	–	1669
2025 Q3	$48.4K	Buy	+27,323	New	+$46.1K	0.01%	992
2025 Q2	–	Sell	-14,355	Closed	-$27.4K	–	1710
2025 Q1	$27.4K	Buy	+14,355	New	+$31.8K	﹤0.01%	1055
2023 Q1	–	Sell	-12,742	Closed	-$39.9K	–	2871
2022 Q4	$39.9K	Buy	+12,742	New	+$39.8K	﹤0.01%	2193

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Securities's GANX Position: Q4 2025 in Review

Two Sigma Securities sold out of Gain Therapeutics (GANX) in Q4 2025, closing a stake of 27,323 shares — an estimated $48.4K sold.

Two Sigma Securities first reported a position in GANX in Q4 2022 and held it in 3 quarters. The position peaked at $48.4K in Q3 2025. 48 funds tracked by Wall St. Rank hold GANX as of Q4 2025.

Two Sigma Securities reported no remaining Gain Therapeutics position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 27,323 Gain Therapeutics shares in Q4 2025, an estimated $48.4K.
Two Sigma Securities first reported a position in Gain Therapeutics in Q4 2022 and held it in 3 quarters.
Two Sigma Securities's Gain Therapeutics position peaked at $48.4K in Q3 2025.
48 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.